Ychloroquine monotherapy, n ( ) Lopinavir/ritonavir monotherapy, n ( ) NEWS2, mean SD Sex (male), n ( ) Age (years), median (IQR) Median length of hospital stay (days), median (IQR) (three.six data missing) Discharge from hospital, n ( ) Physique mass index (kg/m ), median (IQR) (32.1 data missing) Smoking history, n ( ) Variety of coexisting disorders, mean SD Cardiac, n ( ) Pulmonary, n ( ) Hepatic, n ( ) Cancer, n ( ) Hemic illness, n ( ) Diabetes, n ( ) Chronic kidney disease, n ( ) Hypertension, n ( ) Dementia, n ( ) Cerebrovascular, n ( ) Antibiotics, n ( ) Immunosuppressive therapy, n ( ) Fever (38 ), n ( ) Hypotension (systolic blood pressure 100 mmHg), n ( ) Maximum oxygen provide for at the least 12 h (L/ min), median (IQR) C-reactive protein (mg/L), median (IQR) Interleukin-6 (pg/mL), median (IQR) Lactate dehydrogenase (U/L), mean SD (three.six data missing)Handle group n = 14 3 (21.four) 1 (7.1) six.7 two.two 7 (50.0) 70.5 (21.0) 13.0 (13.three) 12 (85.7) 23.4 (7.7) 1 (7.1) two.1 1.6 six (42.9) 1 (7.1) two (14.3) 2 (14.3) two (14.three) three (21.four) three (21.four) 7 (50) 1 (7.1) 3 (21.four) 7 (50.0) 1 (7.1) 13 (92.9) 6 (42.9) 0 (three.0) 52.8 (102.six) 59.9 (90.1) 416.1 154.Triple therapy (lopinavir/ritonavir and hydroxychloroquine) n =p-value6.five two.two 9 (64.3) 67.0 (26.five) 18.0 (16.8) 13 (92.9) 26.7 (eight.1) four (28.six) 2.9 1.two ten (71.four) 8 (57.1) 1 (7.1) two (14.three) three (21.4) two (14.3) 5 (35.7) six (42.9) 1 (7.1) 3 (21.four) 4 (28.six) 2 (14.three) 14 (one hundred.0) eight (57.1) two.0 (five.3) 115.five (249.5) 184.5 (249.5) 374.three 110.0.797 0.704 0.940 0.080 1.000 0.864 0.326 0.148 0.252 0.013 1.000 1.000 1.000 1.000 0.678 1.000 1.000 1.000 0.440 1.000 1.000 0.706 0.177 0.284 0.032 0.NEWS2, National Early Warning Score; IQR, interquartile variety; SD, typical deviation. Note that data, which are typically distributed (Shapiro-Wilk test) are presented as imply 5-HT3 Receptor Antagonist site normal deviation and data not typically distributed are presented as median (interquartile variety); p0.05. https://doi.org/10.1371/journal.pone.0249760.tAlmost all patients on the ICU cohort developed in-hospital AKI with 80 of patients with triple therapy and 90.five of patients in the control group (p = 0.445, Table 5). 40 of sufferers with triple therapy and 23.eight with the manage group created oliguria or anuria (p = 0.366, Table five) and 40 of sufferers with triple therapy and 28.6 of the handle group required RRT (p = 0.553, Table five and Fig 2B). Urine dipstick evaluation indicated hematuria and proteinuria in both groups. Urine sediment evaluation showed muddy brown casts and indicated acute tubular necrosis in extra than 50 of both groups (p = 1.000, Table five). AKI occurred just after a median of 2.8 four.3 days following admission for the ICU within the triple therapy group and after three.1 five.5 days inside the control group (p = 0.862, Table five).PLOS One particular | https://doi.org/10.1371/journal.pone.0249760 Could 11,six /PLOS ONEAKI after hydroxychloroquine/lopinavir in COVID-Table two. Acute kidney injury and outcome in non-ICU patients. Parameter Baseline serum PLK4 custom synthesis creatinine (mg/dL), mean SD Maximum serum creatinine (mg/dL), median (IQR) Delta serum creatinine (mg/dL), median (IQR) AKI, n ( ) AKI I, n ( ) AKI II, n ( ) AKI III, n ( ) Urine evaluation Hematuria, median (IQR), (23.1 data missing) Proteinuria, median (IQR), (23.1 information missing) Leucocyturia, median (IQR), (23.1 data missing) Duration in between very first day of symptoms and AKI (days), imply SD, (7.1 data missing) Duration amongst initial optimistic test and AKI (days), mean SD Duration of triple therapy (days), imply SD Duration among start off of triple the.